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Figure S1B. Model-projected versus WIHS empiric 24-month survival (CD4 50-199/µl): Examples of selected multi-way sensitivity analyses. Regimen 5 (OBR (2 PIs + 2 NRTIs)). Sensitivity analyses performed using 5 lines of treatment used the regimens listed in the table in the order in which they are presented with the fourth regimen of ENF + OBR followed by Regimen 5 (OBR (2 PIs + 2 NRTIs)). Later regimens differ slightly between the base case 4-regimen scenario compared to the 5-regimen scenario as we assumed that more current regimens would become available to women if they survived more than 12-24 months. The order of regimens reflects the general sequence in which regimens are used. HAART was assumed to be initiated when CD4 cell count reached 200/µl given this was the standard practice during the cohort timeframe over which treatment occurred and survival data was collected. † The probability of late failure is the monthly risk of failing treatment after initial successful viral load suppression at 24 weeks. The estimate is based on a pooled weighted average using reported data from the studies of the HAART regimens used in the analysis. ‡ The ART effect is defined as an independent protective effect of HAART and is modeled as a multiplier which decreases the incidence of opportunistic infections and AIDS-related mortality in patients with virologic failure who remain on HAART. (See methods for details) Delay in CD4 decline 1 year Force failure 10 years ART = antiretroviral therapy; ATV = atazanavir; DRV = darunavir; EFV = efavirenz; HAART = highly active antiretroviral therapy; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitors; NNRTI = non-nucleoside reverse transcriptase inhibitors; OBR = optimized background antiretroviral regimen; PI = protease inhibitor; RAL = raltegravir; RTV = ritonavir; SD = standard deviation; T20 = enfuvirtide * The probability of late failure is the monthly risk of failing treatment after initial successful viral load suppression at 24 weeks. † The ART effect is defined as an independent protective effect of HAART and is modeled as a multiplier which decreases the incidence of opportunistic infections and AIDS-related mortality in patients with virologic failure who remain on HAART. ‡ ATV/r arm, <4 PI mutations § Although the virologic suppression for this regimen was reported at 16 weeks, the model treats it as 24 week data.
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|| We assumed that 50% of the cohort received T20 + OBR (HIV RNA 32.7% suppressed at 24 weeks; CD4 benefit of 119 cells at 48 weeks27) and 50% received MVC + OBR +/-T20 (BID arm: HIV RNA 60.4% suppressed at 24 weeks and a CD4 benefit of 111 cells at 24 weeks25; 46% of these patients received T20). The viral suppression rate and the CD4 benefits reported in this table are weighted averages of these two regimens. Figure   S1 illustrates a subset of one-way sensitivity analyses performed in which treatment efficacy, CD4 gain estimates and ART effect were individually varied. These variables were most influential in reducing the model-projected survival although generally did not achieve simultaneous consistency with both 12 and 24 month survival. Scenarios most consistent with the empiric data at 12 months underestimated survival at 24 months while those most consistent with the empiric data at 24 months overestimated survival at 12 months. Part B of Figure S1 illustrates a sample of multi-way sensitivity analyses that were performed. Using insights from the one-way sensitivity analyses, multi-way sensitivity analyses allowed assumptions to vary by regimen (e.g., decrease in efficacy for 1st and 2nd line ART but an increase in efficacy for 3rd and 4th line ART) and also allowed changes in two or more variables simultaneously (e.g., decrease in efficacy ART and decrease in CD4 gain).
